M&A Deal Summary

XOMA Royalty Acquires Pulmokine

On December 2, 2024, XOMA Royalty acquired life science company Pulmokine for 20M USD

Acquisition Highlights
  • This is XOMA Royalty’s 1st transaction in the Life Science sector.
  • This is XOMA Royalty’s largest (disclosed) transaction.
  • This is XOMA Royalty’s 1st transaction in the United States.
  • This is XOMA Royalty’s 1st transaction in New York.

M&A Deal Summary
Date 2024-12-02
Target Pulmokine
Sector Life Science
Buyer(s) XOMA Royalty
Deal Type Add-on Acquisition
Deal Value 20M USD
Advisor(s) Gibson, Dunn & Crutcher (Legal)

Target

Pulmokine

Rensselaer, New York, United States
Pulmokine specializes in developing treatments for pulmonary arterial hypertension (PAH) and other pulmonary diseases. Pulmokine is based in Rensselaer, New York.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

XOMA Royalty

Emeryville, California, United States
Category Company
Sector Life Science
Employees13
Revenue 4M USD (2023)
DESCRIPTION

XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty is based in Emeryville, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal